Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q4 2016 · 10-K
Revenue$62.37M$62.37M+42.8% vs Q4 2015 Net Income$14.32M$14.32M+109.0% vs Q4 2015 EPS Diluted$0.26$0.26+85.7% vs Q4 2015 Operating Income$16,296,000+106.8% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$24,637,000+29.2% Margins · derivedOperating margin26.1%+8.1 pt vs Q4 2015
Net margin23.0%+7.3 pt vs Q4 2015
ended Dec 31, 2016 · filed Mar 16, 2017 · 75 d after period end